| General Information | |
|---|---|
| ZINC ID | ZINC000003938515 |
| Molecular Weight (Da) | 494 |
| SMILES | Nc1c(C(=O)c2ccccc2)oc2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12 |
| Molecular Formula | C26Cl3N2O2 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 131.415 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 33 |
| LogP | 7.76 |
| Activity (Ki) in nM | 436.516 |
| Polar Surface Area (PSA) | 69.12 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.058 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 27 |
| Fraction csp3 | 0 |
| Ilogp | 4.11 |
| Xlogp3 | 8.31 |
| Wlogp | 7.94 |
| Mlogp | 4.7 |
| Silicos-it log p | 7.55 |
| Consensus log p | 6.52 |
| Esol log s | -8.48 |
| Esol solubility (mg/ml) | 0.00000164 |
| Esol solubility (mol/l) | 3.33E-09 |
| Esol class | Poorly sol |
| Ali log s | -9.63 |
| Ali solubility (mg/ml) | 0.00000011 |
| Ali solubility (mol/l) | 2.37E-10 |
| Ali class | Poorly sol |
| Silicos-it logsw | -11.73 |
| Silicos-it solubility (mg/ml) | 9.15E-10 |
| Silicos-it solubility (mol/l) | 1.85E-12 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -3.41 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 3 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.87 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -8.108 |
| Logd | 4.9 |
| Logp | 6.997 |
| F (20%) | 0.007 |
| F (30%) | 0.862 |
| Mdck | 6.21E-06 |
| Ppb | 1.0351 |
| Vdss | 0.937 |
| Fu | 0.0061 |
| Cyp1a2-inh | 0.928 |
| Cyp1a2-sub | 0.2 |
| Cyp2c19-inh | 0.786 |
| Cyp2c19-sub | 0.054 |
| Cl | 4.071 |
| T12 | 0.011 |
| H-ht | 0.816 |
| Dili | 0.989 |
| Roa | 0.523 |
| Fdamdd | 0.891 |
| Skinsen | 0.031 |
| Ec | 0.003 |
| Ei | 0.276 |
| Respiratory | 0.139 |
| Bcf | 2.959 |
| Igc50 | 5.611 |
| Lc50 | 7.314 |
| Lc50dm | 6.615 |
| Nr-ar | 0.218 |
| Nr-ar-lbd | 0.767 |
| Nr-ahr | 0.99 |
| Nr-aromatase | 0.961 |
| Nr-er | 0.897 |
| Nr-er-lbd | 0.801 |
| Nr-ppar-gamma | 0.822 |
| Sr-are | 0.982 |
| Sr-atad5 | 0.939 |
| Sr-hse | 0.79 |
| Sr-mmp | 0.952 |
| Sr-p53 | 0.967 |
| Vol | 463.767 |
| Dense | 1.061 |
| Flex | 0.138 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 5 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 3 |
| Acute aquatic toxicity | 1 |
| Toxicophores | 2 |
| Qed | 0.258 |
| Synth | 2.472 |
| Fsp3 | 0 |
| Mce-18 | 28 |
| Natural product-likeness | -0.725 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 1 |
| Gsk | Rejected |
| Goldentriangle | Accepted |